title: A novel subtype of prostacyclin receptor in the central nervous system.
abstract: Recently, in the course of our search for the prostacyclin receptor in the brain, we found a novel subtype, designated as IP2, which was finely discriminated by use of the specific ligand (15R)-16-m-tolyl-17,18,19,20-tetranorisocarbacyclin (15R-TIC) and specifically localized in the rostral part of the brain. In the present study, the tritiated compound 15R-[15-(3)H]TIC was synthesized and utilized for more specific research on IP2. The specificity of binding to rat brain regions was confirmed by use of several prostacyclin derivatives including 15S-TIC. Mapping of 15R- and 15S-[3H]TIC binding in adjacent pairs of frozen sections of rat brain demonstrated a quite similar pattern of distribution in almost all rostral brain regions, indicating that the regions may contain only the IP2 subtype. On the other hand, 15R-[3H]TIC binding was very faint as compared with 15S-[3H]TIC binding in the caudal medullary region. High densities of 15R-[3H]TIC binding sites were shown in the dorsal part of the lateral septal nucleus, thalamic nuclei, limbic structures, and some of the cortical regions. Scatchard plot analysis showed two components of high-affinity 15R-[3H]TIC binding in the rostral regions, one with a K(D) value at approximately 1 nM and the other with approximately 30 nM. These results strengthen our previous finding that a different subtype of prostacyclin receptor is expressed in the CNS, and the map with 15R-[3H]TIC obtained here could guide further studies on the molecular and functional properties of the IP2.
authors.affiliation: Japan Science and Technology Corporation, and Department of Neuroscience, Osaka Bioscience Institute.
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Matsumura
authors.forename: H
authors.initials: H
authors.lastname: Takechi
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Morii
authors.forename: M
authors.initials: M
authors.lastname: Björkman
authors.forename: B
authors.initials: B
authors.lastname: Långström
authors.forename: R
authors.initials: R
authors.lastname: Noyori
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
mesh_terms: D000818:Animals; D001345:Autoradiography; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D015394:Molecular Structure; D009928:Organ Specificity; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000378:metabolism*; D017552:Solitary Nucleus / Q000378:metabolism; D013788:Thalamus / Q000378:metabolism; D014316:Tritium
chemical_list: C119304:16-tolyl-17,18,19,20-tetranorisocarbacyclin; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D014316:Tritium; D011464:Epoprostenol